Navigation Links
Neutron Therapeutics Installs Europe’s First Accelerator-Based Boron Neutron Capture Therapy (BNCT) Platform – On Track for First Cancer Patient Treatment in 2019
Date:4/18/2019

BNCT is a powerful alternative to traditional radiotherapy and proton therapy, with the ability to deliver targeted radiation to cancer cells while sparing surrounding healthy tissue. NTI’s unique and patented neutron source replaces the nuclear reactor in traditional BNCT research platforms. Engineered from the ground up for high reliability and ease of maintenance, NTI’s platform can enable the widespread adoption of BNCT.

In BNCT treatment, a boron carrier compound injected into the blood stream is selectively absorbed by tumor cells. The tumor is irradiated with a therapeutic neutron beam. The neutron beam reacts with the boron, while safely passing through surrounding tissue. The boron reaction produces highly excited alpha particles of very short path lengths (5–9 µm) that destroy tumor cells from the inside with minimal effect on immediately surrounding tissue. BNCT has successfully been used to treat cancer patients in cases where other treatment options have been exhausted. Typical BNCT therapies utilize two patient treatments vs. dozens for traditional radiotherapy, reducing stress on patients while enhancing treatment center efficiency and patient throughput.

The adoption of BNCT has been limited by the lack of neutron sources suitable for hospital environments. NTI’s system is the first accelerator-based neutron source of its kind in operation. NTI’s patented electrostatic accelerator design and proprietary rotating solid lithium target technology deliver excellent performance and reliability.

Helsinki University Hospital is a pioneer in the clinical use of BNCT. Using a research nuclear reactor as the neutron source, HUH has applied BNCT to over 200 cancer patients. Using NTI’s BNCT platform, HUH will continue its leadership in the development of clinical applications for a number of cancer indications. The establishment of the first in-hospital system in Europe at HUH is anticipated to accelerate the pace of clinical studies and drug development for BNCT.

Dr. Johanna Mattson, Director of HUH Cancer Center: “Our past research in BNCT has demonstrated great potential for some of the most difficult and otherwise untreatable cancers. We are eager to continue our work in BNCT with Neutron Therapeutics, and develop more clinical protocols.”

Ted Smick, CEO of NTI: “Our partnership with HUH allows us to learn from some of the most experienced BNCT physicians in the world. We owe the success of our BNCT treatment suite in large part to their deep knowledge and ongoing support.”

During tests conducted in March, HUH and NTI measured epithermal neutron flux from the system’s treatment aperture of 1.34x10? neutrons/cm2/s. This value exceeds 1.0x10? neutrons/cm2/s, the minimum epithermal neutron flux recommended by the International Atomic Energy Agency for BNCT. This successful demonstration of the required neutron flux is considered a major milestone on the path to clinical use of the neutron source.

Bill Buckley, Chairman of NTI: “We are excited about reaching this milestone at such an early stage of the commissioning process. It is a testament to the high-quality design that the NTI team has created. This puts us well on our way to making BNCT widely available to cancer sufferers throughout the world.”

Helsinki University Hospital is responsible for providing treatment for rare and severe diseases to patients from all over Finland. HUH is an OECI-designated comprehensive cancer center, underscoring their internationally recognized leadership in cancer treatment. As a university hospital, HUH is committed to the continued advancement and improvement of patient care.

Neutron Therapeutics is a Boston-area medical equipment company founded in 2015 by New Zealander, Bill Buckley. The mission of NTI is to provide innovative technology solutions that will enable BNCT to realize its maximum potential in the treatment of difficult cancers.

The Neutron Therapeutics neutron source is not approved for commercial or clinical use by the FDA or EMA or other regulatory body.

For More Information, please contact inquiries(at)nt-bnct.com, or visit us online at:
Neutron Therapeutics - http://www.neutrontherapeutics.com
Helsinki University Hospital - http://www.hus.fi

Read the full story at https://www.prweb.com/releases/neutron_therapeutics_installs_europes_first_accelerator_based_boron_neutron_capture_therapy_bnct_platform_on_track_for_first_cancer_patient_treatment_in_2019/prweb16250500.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. Seattle Scientists Publish Results of Neutron Therapy Study for Mesothelioma, According to Surviving Mesothelioma
2. Saol Therapeutics Announces CDC has Updated Information Related to Use and Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])
3. uBiome Receives Patent for Diagnostics and Therapeutics for Endocrine System Conditions
4. uBiome Receives Patent for Diagnostics and Therapeutics for Microbiome Functional Features
5. Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
6. Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
7. Thermo Fisher Scientific Enables Targeted Therapeutics by Utilizing Transcriptomics
8. NEW Ingredient: Euromed SA Partners with Biotherapeutics Inc. to Launch the First Abscisic Acid Nutritional Ingredient to Market
9. Innovations Series Explores Advances in Therapeutics for Treatment and Diagnosis of Disease
10. Open Therapeutics and AuthorAID to Cooperate on Advancing Scientific Knowledge
11. Blue Door Therapeutics Paving the Way to Treat the Opioid Epidemic with $2 Million Dollar Treatment Center in North Scottsdale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... Ky. (PRWEB) , ... July 17, 2019 , ... ... awarded to Eastern Kentucky University’s online Family Nurse Practitioner program. The honor is ... quality in distance education. , The Catalyst Awards honor institutions from around ...
(Date:7/17/2019)... ... July 17, 2019 , ... Becker's ... critical access hospitals. , The men and women included on this list lead ... mergers and EHR implementations as well as the construction of satellite clinics and ...
(Date:7/17/2019)... ... July 17, 2019 , ... ICD10monitor, an online ... coding set, is launching an exclusive educational webcast subscription service featuring 40 original ... officials announced this week. , The ICD10monitor webcast portfolio already includes sought-after ...
(Date:7/17/2019)... ... July 17, 2019 , ... This past Saturday, ... Smiles for Everyone Foundation . Over 50 underserved patients were welcomed at the Mesquite ... more while celebrating the summer season. Individuals were referred to the event through local ...
(Date:7/17/2019)... ... July 17, 2019 , ... A new study led by researchers ... American Medical Association (JAMA), shows for the first time that New York’s sepsis ... Sepsis is the body’s extreme response to infection. It kills more than 275,000 Americans ...
Breaking Medicine News(10 mins):
(Date:7/17/2019)... ... ... Highmark Health, Allegheny Health Network (AHN) and the Pittsburgh Riverhounds today joined ... for what will be one of the largest health and sports complexes in the ... the Montour Trail, the complex is being developed by the Riverhounds organization and expects ...
(Date:7/17/2019)... ... ... Eargo the direct-to-consumer health tech company destigmatizing hearing loss through ... hires: CFO Adam Laponis (from Tesla, Inc.), CMO Shiv Singh (from Visa, Inc., PepsiCo, ... , The new hires come on the heels of Eargo’s $52 million Series ...
(Date:7/17/2019)... SAN DIEGO (PRWEB) , ... July 17, 2019 ... ... today announced that DFree ®, the first wearable for urinary incontinence, will ... Stanford University in Stanford, CA, on July 26, 2019. The Innovation Showcase recognizes ...
Breaking Medicine Technology: